Abingworth closes Fund IV at $350m
The Anglo-American life sciences VC firm has exceeded the original $275m target for their Abingworth Bioventures IV fund (ABV IV), which was more than two times over-susbscribed.
The Anglo-American life sciences VC firm has exceeded the original $275m target for their Abingworth Bioventures IV fund (ABV IV), which was more than two times over-susbscribed.
Copyright PEI Media
Not for publication, email or dissemination